Figure 8. Membrane PD-L1 levels positively correlate with MIB2 expression in non–small cell lung cancer.

(A) Representative IHC images for MIB2 and PD-L1 from nivolumab-treated patients with non–small cell lung cancer (NSCLC). The top two rows show images from a nonresponder; the bottom two rows show images from a responder. Scale bar: 500 μm (first and third rows); 50 μm (second and fourth rows). (B) Scatterplot showing the correlation between MIB2 and membrane PD-L1 levels in NSCLC specimens. Each plot represent 1 patient (n = 31). (C) Pie chart of MIB2 and membrane PD-L1 levels in 31 NSCLC specimens. (D) The percentage of responders and nonresponders displaying low or high MIB2 protein levels in 31 NSCLC specimens. (E) The percentages of patients with tumors exhibiting low or high MIB2 levels in the groups with partial response (PR), stable disease (SD), or progressive disease (PD). (F) Change in the diameter of tumors from patients with NSCLC treated with PD-1 mAb. Pink represents increased tumor diameter; and blue represents decreased tumor diameter. (G and H) Scatterplot showing the correlation between (G) MIB2 or (H) membrane PD-L1 levels and the response to PD-1 mAb treatment. (I) Naive Bayes model to classify 3 response groups based on the ratio of MIB2 and PD-L1 IHC scores. **P < 0.01; ***P < 0.001 by χ² test for contingency (D and E).